“…Finally, this study is integrated in a larger trial, 34 therefore, a specific sample size calculation to establish MCIDs was not performed, which might have underpowered this study for its goal. Nevertheless, similar samples sizes have been used to establish MCIDs in other studies, 40,68,69 and the fact that all MCIDs fell within the recommended range of 6 to 10% change in the scale range, which corresponded to a desirable effect size of 0.2 to 0.5, 19,38,48 strengthens the validity of our estimates. Moreover, to our best knowledge, this is the first study to provide MCIDs estimations for LCQ and CASA-Q in patients with COPD; thus, we believe that our MCIDs estimates can be useful for health professional and policy makers, ensuring they are used with caution and in accordance with each clinical context.…”